PL3085386T3 - Sposób hamowania resorpcji kości - Google Patents

Sposób hamowania resorpcji kości

Info

Publication number: PL3085386T3
Authority: PL; Poland
Prior art keywords: bone resorption; inhibiting bone; inhibiting; resorption; bone
Prior art date: 2007-09-17

Application number

PL16162068T

Other languages

English (en)

Inventor

Ian Desmond Padhi

Graham Richard Jang

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-17

Filing date

2008-09-17

Publication date

2020-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40371592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3085386(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-17 Application filed by Amgen Inc. filed Critical Amgen Inc.

2020-11-30 Publication of PL3085386T3 publication Critical patent/PL3085386T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)

PL16162068T 2007-09-17 2008-09-17 Sposób hamowania resorpcji kości PL3085386T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US97302407P	2007-09-17	2007-09-17
PCT/US2008/076679 WO2009039175A2 (en)	2007-09-17	2008-09-17	Method for inhibiting bone resorption
EP08832690.5A EP2195026B1 (en)	2007-09-17	2008-09-17	Anti-sclerostin antibodies
EP16162068.7A EP3085386B1 (en)	2007-09-17	2008-09-17	Method for inhibiting bone resorption
EP12180292.0A EP2556841B9 (en)	2007-09-17	2008-09-17	Method for inhibiting bone resorption

Publications (1)

Publication Number	Publication Date
PL3085386T3 true PL3085386T3 (pl)	2020-11-30

Family

ID=40371592

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL20174310.1T PL3725329T3 (pl)	2007-09-17	2008-09-17	Sposób hamowania resorpcji kości
PL08832690T PL2195026T3 (pl)	2007-09-17	2008-09-17	Przeciwciała przeciw sklerostynie
PL12180292.0T PL2556841T3 (pl)	2007-09-17	2008-09-17	Sposób hamowania resorpcji kości
PL16162068T PL3085386T3 (pl)	2007-09-17	2008-09-17	Sposób hamowania resorpcji kości

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL20174310.1T PL3725329T3 (pl)	2007-09-17	2008-09-17	Sposób hamowania resorpcji kości
PL08832690T PL2195026T3 (pl)	2007-09-17	2008-09-17	Przeciwciała przeciw sklerostynie
PL12180292.0T PL2556841T3 (pl)	2007-09-17	2008-09-17	Sposób hamowania resorpcji kości

Country Status (21)

Country	Link
US (7)	US8017120B2 (pl)
EP (5)	EP3725329B1 (pl)
JP (2)	JP5643094B2 (pl)
AR (2)	AR068471A1 (pl)
AU (1)	AU2008302313C1 (pl)
CA (2)	CA3170836A1 (pl)
CL (1)	CL2008002775A1 (pl)
CY (3)	CY1114961T1 (pl)
DK (4)	DK2556841T3 (pl)
ES (4)	ES2445792T3 (pl)
FI (1)	FI3725329T3 (pl)
HK (1)	HK1182017A1 (pl)
HR (4)	HRP20240493T3 (pl)
HU (3)	HUE066466T2 (pl)
LT (3)	LT3085386T (pl)
MX (1)	MX2010002971A (pl)
PL (4)	PL3725329T3 (pl)
PT (4)	PT2556841T (pl)
SI (4)	SI2195026T1 (pl)
TW (2)	TWI612972B (pl)
WO (1)	WO2009039175A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA01005275A (es)	1998-11-27	2003-06-06	Darwin Discovery Ltd	Composiciones y metodos para aumentar la mineralizacion de huesos.
ES2586401T3 (es)	2003-06-16	2016-10-14	Ucb Pharma S.A.	Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EP2423226A3 (en) *	2006-11-10	2012-05-30	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2460828A3 (en) *	2006-11-10	2012-08-08	UCB Pharma, S.A.	Antibodies and diagnostics
LT3345607T (lt)	2006-12-29	2023-01-10	Ossifi-Mab Llc	Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20090142766A1 (en) *	2007-11-09	2009-06-04	Washington University In St. Louis	Methods for measuring the metabolism of cns derived biomolecules in vivo
CN101896201A (zh) *	2007-12-14	2010-11-24	安进公司	使用抗硬骨素抗体治疗骨折的方法
TWI564021B (zh)	2008-04-11	2017-01-01	Chugai Pharmaceutical Co Ltd	Repeated binding of antigen to antigen binding molecules
CA2798888C (en)	2010-05-14	2019-10-01	Amgen Inc.	High concentration antibody formulations
PT3111954T (pt)	2010-11-05	2019-07-10	Novartis Ag	Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17
WO2012073992A1 (ja)	2010-11-30	2012-06-07	中外製薬株式会社	複数分子の抗原に繰り返し結合する抗原結合分子
JP2014502276A (ja) *	2010-12-02	2014-01-30	ワシントン・ユニバーシティ	アミロイドプラーク関連症状の治療のための組成物及び方法
US9133272B2 (en)	2011-03-01	2015-09-15	Amgen Inc.	Bispecific binding agents
KR20140018315A (ko)	2011-03-25	2014-02-12	암젠 인크	항스클러로스틴 항체 결정 및 이의 제제
EP2699261B1 (en) *	2011-04-19	2018-07-11	Amgen Inc.	Method for treating osteoporosis
WO2012149246A1 (en)	2011-04-29	2012-11-01	Novartis Ag	Methods of treating squamous cell carcinoma related applications
EP2739311B9 (en) *	2011-08-04	2018-09-19	Amgen Inc.	Method for treating bone gap defects
CN103957915A (zh) *	2011-09-22	2014-07-30	埃克塞里艾克西斯公司	治疗骨质疏松症的方法
US9657090B2 (en)	2011-12-28	2017-05-23	Amgen Inc.	Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
EP2869844B2 (en) *	2012-07-05	2023-06-21	UCB Pharma S.A.	Treatment for bone diseases
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014118705A1 (en)	2013-01-31	2014-08-07	Novartis Ag	Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
EP3200832B1 (en)	2014-09-30	2020-07-29	Washington University	Tau kinetic measurements
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
PL3478719T3 (pl)	2016-12-21	2021-10-25	Mereo Biopharma 3 Limited	Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kości
US10961305B2 (en)	2016-12-21	2021-03-30	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
WO2018139623A1 (en)	2017-01-30	2018-08-02	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
CN112166120B (zh) *	2018-03-30	2024-09-10	安姆根有限公司	C末端抗体变体
GB201810746D0 (en)	2018-06-29	2018-08-15	Mereo Biopharma 3 Ltd	Use of sclerostin antagonist
CN111658821A (zh) *	2020-06-03	2020-09-15	深圳市百吉因生物科技有限公司	负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
TW202430215A (zh)	2022-12-14	2024-08-01	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	用於將治療劑遞送至骨之組成物和方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4411993A (en) *	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) *	1981-10-19	1984-01-24	Laipply Thomas C	One piece alcohol preparation device
USRE32011E (en) *	1981-12-14	1985-10-22	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) *	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) *	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) *	1984-05-11	1986-01-09	Matter + Siegmann Ag, Wohlen	Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) *	1984-12-03	1990-02-20	Teijin Limited	Monoclonal antibody to human protein C
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
RO114469B1 (ro)	1987-12-15	1999-04-30	Gene Shears Pty Ltd	Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en) *	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5244805A (en)	1989-05-17	1993-09-14	University Of Georgia Research Foundation, Inc.	Baculovirus expression vectors
US5177197A (en)	1990-02-27	1993-01-05	Ludwig Institute For Cancer Research	Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JP3218637B2 (ja) *	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
JP2958076B2 (ja) *	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) *	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) *	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JPH04141095A (ja)	1990-10-02	1992-05-14	Chemo Sero Therapeut Res Inst	組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) *	1990-10-12	1991-12-03	Trustees Of The University Of Pennsylvania	Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
JPH06502311A (ja)	1990-10-22	1994-03-17	フォックス・チェイス・キャンサー・センター	Ｒｎａ療法を提供するためのｄｎａ構造
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
WO1992019759A1 (en)	1991-04-25	1992-11-12	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human interleukin 6 receptor
US5807683A (en)	1992-11-19	1998-09-15	Combichem, Inc.	Combinatorial libraries and methods for their use
WO1994028929A1 (en) *	1993-06-07	1994-12-22	Genentech, Inc.	Hiv envelope polypeptides
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5453492A (en) *	1993-07-28	1995-09-26	La Jolla Cancer Research Foundation	60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) *	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en) *	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
EP0756628B1 (en)	1994-04-29	2007-11-14	Curis, Inc.	Morphogenic protein-specific cell surface receptors and uses therefor
US5738996A (en)	1994-06-15	1998-04-14	Pence, Inc.	Combinational library composition and method
DE4427221A1 (de)	1994-08-01	1996-02-08	Gsf Forschungszentrum Umwelt	Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en)	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
US6057421A (en) *	1994-11-30	2000-05-02	Immpheron, Inc.	Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5723750A (en)	1995-01-12	1998-03-03	Vanderbilt University	Transgenic plants expressing disassembly deficient viral coat proteins
US5795587A (en) *	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) *	1995-06-05	1996-12-12	Gregg A. Hastings	Human ccn-like growth factor
US5738868A (en) *	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
WO1997044461A2 (en) *	1996-05-22	1997-11-27	Novopharm Biotech, Inc.	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6133426A (en) *	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
US5989909A (en)	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
WO1998046588A2 (en) *	1997-04-11	1998-10-22	Neorx Corporation	Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6278039B1 (en)	1997-05-28	2001-08-21	Axys Pharmaceuticals, Inc.	C. elegans deletion mutants
ES2301198T3 (es)	1997-06-12	2008-06-16	Novartis International Pharmaceutical Ltd.	Polipeptidos artificiales de anticuerpos.
US6075007A (en)	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
EP1000152A2 (en)	1997-08-01	2000-05-17	Genset	5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
US6815201B2 (en) *	1997-09-08	2004-11-09	The Public Health Research Institute Of The City Of New York, Inc.	HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6251588B1 (en)	1998-02-10	2001-06-26	Agilent Technologies, Inc.	Method for evaluating oligonucleotide probe sequences
GB9818881D0 (en) *	1998-08-28	1998-10-21	Glaxo Group Ltd	Compounds
US6544485B1 (en) *	2001-01-29	2003-04-08	Sharper Image Corporation	Electro-kinetic device with enhanced anti-microorganism capability
MXPA01005275A (es) *	1998-11-27	2003-06-06	Darwin Discovery Ltd	Composiciones y metodos para aumentar la mineralizacion de huesos.
US20040009535A1 (en) *	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
CN1345334A (zh)	1999-01-29	2002-04-17	伊姆克罗尼系统公司	对kdr特异的抗体及其应用
US6110462A (en)	1999-03-03	2000-08-29	The Scripps Research Institute	Enzymatic DNA molecules that contain modified nucleotides
EP1683811B1 (en)	1999-06-09	2009-08-19	Genentech, Inc.	Methods for the diagnosis of tumors
US6197592B1 (en) *	1999-07-15	2001-03-06	Bio-Rad Laboratories, Inc.	Clinical control materials for detection of bone resorptive markers
JP2003525611A (ja)	2000-03-02	2003-09-02	アムジェンインコーポレーテッド	コルディン様−２分子およびその使用
AU2001265198A1 (en) *	2000-06-01	2001-12-11	Amgen Inc.	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (ja)	2000-06-19	2004-07-08	エフ．ホフマン−ラ　ロシュ　アーゲー	オステオレビン遺伝子多型性
AU2002216610A1 (en)	2000-09-01	2002-04-02	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE442862T2 (de)	2000-10-12	2009-10-15	Genentech Inc	Niederviskose konzentrierte proteinformulierungen
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) *	2001-03-13	2002-09-13	The Minister Of National Defence	Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) *	2001-09-17	2003-04-10	Bayer Cropscience Ag	DELTA·1·-Pyrroline
US7261892B2 (en)	2001-11-27	2007-08-28	Celltech R&D Limited	Methods for diagnosis and treatment of epithelial-derived cancers
NZ533051A (en)	2001-12-06	2006-10-27	Biocontrol Systems Inc	Sample collection and testing system
US20030186915A1 (en) *	2002-02-11	2003-10-02	Yang Pan	Regulatory polynucleotides and uses thereof
US7332276B2 (en) *	2002-03-01	2008-02-19	Celltech R&D, Inc.	Methods to increase or decrease bone density
US7799523B2 (en)	2002-04-03	2010-09-21	Celltech R & D, Inc.	Association of polymorphisms in the SOST gene region with bone mineral density
FR2838379B1 (fr)	2002-04-12	2005-06-24	Valeo Climatisation	Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US7893218B2 (en) *	2003-06-16	2011-02-22	Stowers Institute For Medical Research	Antibodies that specifically bind SOST peptides
US20040023356A1 (en) *	2002-06-14	2004-02-05	Robb Krumlauf	Wise/Sost nucleic acid sequences and amino acid sequences
EP1572122A4 (en)	2002-11-01	2008-04-09	Us Gov Health & Human Serv	METHOD FOR PREVENTING INFECTIONS FROM BIOLOGICAL TERRORISM AGENTS WITH IMMUNOSTIMULATORY CPG OLIGONUCLEOTIDES
EP2314691A3 (en)	2002-11-14	2012-01-18	Dharmacon, Inc.	Fuctional and hyperfunctional siRNA
DE10255152A1 (de)	2002-11-26	2004-06-03	Von Langen Ursula Lang	Schadstoffsauger
US7642238B2 (en) *	2002-12-05	2010-01-05	Shaughnessy John D	Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) *	2003-01-15	2004-07-22	Rajiv Doshi	System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
ES2379689T3 (es)	2003-03-14	2012-04-30	Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware	Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo
EP1608733B1 (en)	2003-04-02	2011-12-07	Dharmacon, Inc.	Modified polynucleotides for use in rna interference
US20050158303A1 (en)	2003-04-04	2005-07-21	Genentech, Inc.	Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es)	2003-04-23	2009-08-04	Centro Inmunologia Molecular	Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
ES2586401T3 (es)	2003-06-16	2016-10-14	Ucb Pharma S.A.	Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
US8461155B2 (en)	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
DE602005017362D1 (de)	2004-02-06	2009-12-10	Dharmacon Inc	Stabilisierte rnas als transfektionskontrollen und silencing-reagentien
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050267233A1 (en)	2004-05-25	2005-12-01	Joshi Ashok V	Anti-microbial handle system
MX2007001221A (es)	2004-08-04	2007-03-23	Amgen Inc	Anticuerpos para proteina dickkopf-1 (dkk-1).
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8541177B2 (en) *	2006-01-13	2013-09-24	A Chan Holding B.V.	Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
EP2423226A3 (en)	2006-11-10	2012-05-30	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2460828A3 (en)	2006-11-10	2012-08-08	UCB Pharma, S.A.	Antibodies and diagnostics
US20080120672A1 (en)	2006-11-21	2008-05-22	Francesco Caggioni	Methods and Apparatus for Weighted Multicasting of Data Streams
LT3345607T (lt)	2006-12-29	2023-01-10	Ossifi-Mab Llc	Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą
BRPI0807205A2 (pt)	2007-02-02	2014-07-22	Novartis Ag	Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso
EP2131860B1 (en)	2007-03-20	2013-12-18	Eli Lilly & Company	Anti-sclerostin antibodies
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX2010004761A (es)	2007-11-02	2010-05-19	Novartis Ag	Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
CN101896201A (zh)	2007-12-14	2010-11-24	安进公司	使用抗硬骨素抗体治疗骨折的方法
SG191639A1 (en)	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
AR075715A1 (es)	2009-03-05	2011-04-20	Novartis Ag	Formulacion de anticuerpo liofilizado
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
WO2010130830A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
EP2632951B1 (en)	2010-10-27	2017-08-02	Amgen Inc.	Dkk1 antibodies and methods of use

2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/en active
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 PL PL20174310.1T patent/PL3725329T3/pl unknown
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en active Application Filing
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 HR HRP20240493TT patent/HRP20240493T3/hr unknown
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 HU HUE20174310A patent/HUE066466T2/hu unknown
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 ES ES20174310T patent/ES2975587T3/es active Active
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 EP EP23219258.3A patent/EP4335510A3/en active Pending
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
2011
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
- 2013-08-12 HK HK13109416.2A patent/HK1182017A1/zh unknown
2014
- 2014-02-18 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
2021
- 2021-07-15 US US17/376,304 patent/US20210340236A1/en active Pending

Also Published As

Publication number	Publication date
TW200930403A (en)	2009-07-16
CA2699905A1 (en)	2009-03-26
EP3725329A1 (en)	2020-10-21
JP2010539190A (ja)	2010-12-16
US20130287764A1 (en)	2013-10-31
CA3170836A1 (en)	2009-03-26
PT3085386T (pt)	2020-09-15
PL3725329T3 (pl)	2024-06-10
US8440193B2 (en)	2013-05-14
HRP20240493T3 (hr)	2024-07-05
CY1117908T1 (el)	2017-05-17
DK3085386T3 (da)	2020-09-28
HRP20201438T1 (hr)	2020-11-27
EP2556841B1 (en)	2016-05-11
AU2008302313B2 (en)	2013-10-31
PT2195026E (pt)	2014-03-31
TW201622747A (zh)	2016-07-01
US20210340236A1 (en)	2021-11-04
MX2010002971A (es)	2010-08-10
AU2008302313C1 (en)	2014-04-03
LT3725329T (lt)	2024-03-25
US9089553B2 (en)	2015-07-28
EP3085386B1 (en)	2020-06-24
PT2556841T (pt)	2016-07-25
SI3085386T1 (sl)	2020-11-30
DK3725329T3 (da)	2024-03-18
CY1114961T1 (el)	2016-12-14
ES2581754T3 (es)	2016-09-07
US11091537B2 (en)	2021-08-17
HUE030168T2 (en)	2017-05-29
SI3725329T1 (sl)	2024-04-30
JP5764704B2 (ja)	2015-08-19
CY1123463T1 (el)	2022-03-24
HK1182017A1 (zh)	2013-11-22
HRP20160872T1 (hr)	2016-09-23
TWI526222B (zh)	2016-03-21
ES2815677T3 (es)	2021-03-30
DK2556841T3 (en)	2016-08-15
AU2008302313A1 (en)	2009-03-26
EP2556841B9 (en)	2017-09-06
AR068471A1 (es)	2009-11-18
US20150274817A1 (en)	2015-10-01
US8329176B2 (en)	2012-12-11
US20110262433A1 (en)	2011-10-27
US8017120B2 (en)	2011-09-13
LT2556841T (lt)	2016-09-12
HRP20140153T1 (hr)	2014-04-25
US10273293B2 (en)	2019-04-30
PL2195026T3 (pl)	2014-05-30
JP2015038076A (ja)	2015-02-26
CA2699905C (en)	2023-09-05
LT3085386T (lt)	2020-11-25
EP2195026B1 (en)	2013-12-25
US20190100580A1 (en)	2019-04-04
EP2556841A1 (en)	2013-02-13
HUE050653T2 (hu)	2020-12-28
EP4335510A2 (en)	2024-03-13
EP4335510A3 (en)	2024-06-26
HUE066466T2 (hu)	2024-08-28
TWI612972B (zh)	2018-02-01
EP3725329B1 (en)	2024-01-31
PL2556841T3 (pl)	2016-11-30
ES2445792T3 (es)	2014-03-05
US20110268730A1 (en)	2011-11-03
EP2195026A2 (en)	2010-06-16
EP3085386A1 (en)	2016-10-26
WO2009039175A3 (en)	2009-05-07
ES2975587T3 (es)	2024-07-09
SI2556841T1 (sl)	2016-10-28
PT3725329T (pt)	2024-03-14
US20090074763A1 (en)	2009-03-19
DK2195026T3 (da)	2014-03-03
SI2195026T1 (sl)	2014-04-30
FI3725329T3 (fi)	2024-03-18
WO2009039175A2 (en)	2009-03-26
AR109995A2 (es)	2019-02-13
JP5643094B2 (ja)	2014-12-17
CL2008002775A1 (es)	2008-11-07

Publication	Publication Date	Title
HK1182017A1 (zh)	2013-11-22	抑制骨吸收的方法
EP2367489A4 (en)	2013-05-29	CERCLAGE SYSTEM FOR BONE
EP2355726A4 (en)	2014-07-16	INTRAMEDULLARY REPAIR SYSTEM FOR BONE BREAKS
EP2094350A4 (en)	2010-07-14	GROUPED ELECTRODES FOR BACKMARK STIMULATION
IL198649A0 (en)	2010-02-17	Interspinous implant
EP2079414A4 (en)	2011-12-28	SYSTEM FOR CHEMOHYPER THERMAL TREATMENT
IL211523B (en)	2018-04-30	Devices for increasing the density of jaw-skull bones
EP2171169A4 (en)	2013-07-31	METHOD
EP2308409A4 (en)	2012-06-27	DRILL FOR AN IMPLANT
EP2148708A4 (en)	2012-12-05	COMPOSITION FOR PROMOTING BONE FORMATION
EP2194893A4 (en)	2014-08-06	IMPLANT SYSTEM
PL2002702T3 (pl)	2016-05-31	Sposób wstępnego kiełkowania materiału siewnego
GB0703366D0 (en)	2007-03-28	Method
GB2456999B (en)	2011-04-27	Method for preparing 2-deoxy-L-ribose
EP2058409A4 (en)	2012-12-12	HEAT TREATMENT PROCESS
GB0600228D0 (en)	2006-02-15	Inactivation method
IL202261A0 (en)	2010-06-16	Method for pain control
EP2192904A4 (en)	2010-08-25	METHODS OF INHIBITING TGF-
GB0705321D0 (en)	2007-04-25	Method
EP2208733A4 (en)	2014-08-06	FOOD FOR INHIBITING BONE RESORPTION
ZA201002110B (en)	2010-11-24	Method for stabilizing quercetin
ZA200903242B (en)	2010-08-25	Treatment for multiple myeloma
PL1842931T3 (pl)	2014-07-31	Sposób obróbki cieplnej
HUP0800040A2 (en)	2009-06-29	Set for fixing bones
PL381143A1 (pl)	2008-05-26	Sposób otrzymywania 2-metyloglicydolu